Toast

I understand that you are arguing, but what is your argument? You're bullish Vertex because " the HCV market isn't really that big after a few years"? I'm uncertain how that helps Vertex. Incivek revenues have stabilized around $1.6b/yr in the US; you state that will be the case for 2 years. What will replace that revenue stream? Kalydeco? I think everyone would agree the revenues are limited without an additional corrector. 809, 661? What probabilities of success do you assign to each and what probability adjusted revenues are you using for each?Or does your projected revenue stream come from 509, 765? If so what revenue projections do you have for each. If you've done the analysis I'd love to see it and reconsider my position.

This is your quote from the past:"Vertex needs to be taken out and shot to put everyone who owns it out of their misery."

I'm not going to share what I know, however, I do expect some short-term weakness. GILD spent way too much money on VRUS for a share of this market. BMY is going to yank their drug and use their own nuc from INHX. VRTX will have a share with their all oral regimen as well.

Yahoo! Finance Worldwide

Quotes are real-time for NASDAQ, NYSE, and NYSEAmex when available. See also delay times for other exchanges. Quotes and other information supplied by independent providers identified on the Yahoo! Finance partner page. Quotes are updated automatically, but will be turned off after 25 minutes of inactivity. Quotes are delayed at least 15 minutes. All information provided "as is" for informational purposes only, not intended for trading purposes or advice. Neither Yahoo! nor any of independent providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein. By accessing the Yahoo! site, you agree not to redistribute the information found therein.